ArticlePharmaceutical research2013
Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis.
Article in Pharmaceutical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines.Molecular pharmaceutics · 2024Review
- The potential of nano- and microparticle-based influenza vaccines with enhanced shelf lives.Nanomedicine (London, England) · 2024Article
- Delivery of small molecule mast cell activators for West Nile Virus vaccination using acetalated dextran microparticles.International journal of pharmaceutics · 2023Article
- Role of site-directed mutagenesis and adjuvants in the stability and potency of anthrax protective antigen.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Review
- Developing Acid-Responsive Glyco-Nanoplatform Based Vaccines for Enhanced Cytotoxic T-lymphocyte Responses Against Cancer and SARS-CoV-2.Advanced functional materials · 2021Article
- Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.Advanced nanobiomed research · 2021Article
- Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications.ACS applied materials & interfaces · 2020Article
- Carbohydrate Conjugates in Vaccine Developments.Frontiers in chemistry · 2020Review
- Electrospray for generation of drug delivery and vaccine particles applied in vitro and in vivo.Materials science & engineering. C, Materials for biological applications · 2019Review
- Biodegradable polymers for modern vaccine development.Journal of industrial and engineering chemistry (Seoul, Korea) · 2019Review
- A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8Biomaterials · 2019Article
- Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.Molecular pharmaceutics · 2018Article
- A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Vaccines for the Prevention of Melioidosis and Glanders.Current tropical medicine reports · 2017Article
- Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Nanoengineering of vaccines using natural polysaccharides.Biotechnology advances · 2015Review
- Oropharyngeal aspiration of Burkholderia mallei and Burkholderia pseudomallei in BALB/c mice.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA rapid immune response is required to prevent death from Anthrax, caused by Bacillus anthracis.
methodWe formulated a vaccine carrier comprised of acetalated dextran microparticles encapsulating recombinant protective antigen (rPA) and resiquimod (a toll-like receptor 7/8 agonist).
resultsWe were able to protect against triplicate lethal challenge by vaccinating twice (Days 0, 7) and then aggressively challenging on Days 14, 21, 28. A significantly higher level of antibodies was generated by day 14 with the encapsulated group compared to the conventional rPA and alum group. Antibodies produced by the co-encapsulated group were only weakly-neutralizing in toxin neutralization; however, survival was not dependent on toxin neutralization, as all vaccine formulations survived all challenges except control groups. Post-mortem culture swabs taken from the hearts of vaccinated groups that did not produce significant neutralizing titers failed to grow B. anthracis.
conclusionsResults indicate that protective antibodies are not required for rapid protection; indeed, cytokine results indicate that T cell protection may play a role in protection from anthrax. We report the first instance of use of a particulate carrier to generate a rapid protective immunity against anthrax.
Indexed as
Identifiers
23354770What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.